Equilibrative nucleoside transporter (ENT)

Equilibrative nucleoside transporters are integral membrane proteins that mediate the passive (facilitative) bidirectional transport of nucleosides and nucleobases across cell membranes, playing a critical role in nucleoside homeostasis by enabling salvage pathway nucleotide, DNA, and RNA synthesis, as well as regulating adenosine levels for purinergic signaling. They constitute the SLC29 gene family, including four human isoforms (ENT1–4), with broad tissue distribution, highest in metabolically active organs. ENTs are key determinants of sensitivity to nucleoside analog drugs used in cancer and antiviral therapy and are targeted by several cardiovascular agents. Certain ENT variants serve as blood group antigens and can be linked to rare genetic syndromes. The function and expression of ENTs, particularly hENT1, are relevant as clinical biomarkers and therapeutic determinants in multiple disease states

Other names

ENTSLC29 (family designation)Nucleoside transporterhENT1 (Human equilibrative nucleoside transporter 1)hENT2, hENT3, hENT4 (isoforms)SLC29A1, SLC29A2, SLC29A3, SLC29A4 (gene symbols for human isoforms)

Facilitative (passive) uniport of nucleosides and nucleobases down their concentration gradient (sodium-independent) Uptake of nucleoside analogs, enhancing intracellular drug levels Inhibition leads to increased extracellular adenosine, affecting cardiovascular and neurologic function Drug inhibitors block nucleoside transport, modulating purinergic signaling and drug efficacy